Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Diagnostics and Research

Fulgent Genetics, Inc. operates as a technology company. The Company develops a proprietary technology platform that integrates sophisticated data comparison and suppression algorithms, adaptive learning software, advanced genetic diagnostics tools, and integrated laboratory processes. Fulgent Genetics offers genetic testing to provide physicians with clinically diagnostic information.
Website: fulgentgenetics.com



Growth: Good revenue growth rate 16.7%, there is acceleration compared to average historical growth rates -14.5%. The revenue growth dynamics is unstable Site traffic for the last 3 months showed a change of -81.0%

Profitability: LTM EBITDA margin is negative, -14.9%. On average the margin is improving steadily. Gross margin is high, +42.2%. In the last quarter the company beat the estimated EPS. The company was ahead of estimated EPS in 100% of quarters (showing a gain of +$0.37 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 99.5% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 22.4% higher than minimum and 54.2% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued 0.5x by EV / Sales multiple

Key Financials (Download financials)

Ticker: FLGT
Share price, USD:  (+3.4%)18.7
year average price 24.24  


year start price 21.29 2025-06-04

max close price 30.85 2025-11-25

min close price 15.70 2026-05-16

current price 18.70 2026-06-03
Common stocks: 30 749 000

Dividend Yield:  0.0%
EV / Sales: -0.7x
Margin (EBITDA LTM / Revenue): -14.9%
Fundamental value created in LTM:
Market Cap ($m): 575
Net Debt ($m): -788
EV (Enterprise Value): -213
Price to Book: 0.5x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-12-23zacks.com

FLGT to Acquire Bako & StrataDx Assets to Expand Pathology Platform

2025-12-22businesswire.com

Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx

2025-11-07businesswire.com

Fulgent Reports Third Quarter 2025 Financial Results

2025-08-02fool.com

Fulgent (FLGT) Q2 Revenue Jumps 16%

2025-08-01zacks.com

Fulgent Genetics, Inc. (FLGT) Surpasses Q2 Earnings and Revenue Estimates

2025-06-16accessnewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc. - FLGT

2025-06-06globenewswire.com

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Fulgent Genetics, Inc.  - FLGT

2025-05-28globenewswire.com

INVESTIGATION ALERT: Edelson Lechtzin LLP Announces Investigation Of Fulgent Genetics, Inc. (NASDAQ: FLGT) and Encourages Investors with Substantial Losses or Witnesses with Relevant Information to Contact the Firm

2025-05-24businesswire.com

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm

2025-05-22globenewswire.com

FULGENT ALERT: Bragar Eagel & Squire, P.C. is Investigating Fulgent Genetics, Inc. on Behalf of Fulgent Stockholders and Encourages Investors to Contact the Firm
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-01 2024-11-08 2024-08-02 2024-05-03 2023-11-03 2023-08-04 2023-05-05 2022-11-07
acceptedDate 2025-11-07 07:14:18 2025-08-01 07:09:52 2025-02-28 07:15:43 2024-11-08 07:17:27 2024-08-02 07:38:25 2024-05-03 07:34:20 2024-02-28 17:03:25 2023-11-03 07:31:48 2023-08-04 07:14:47 2023-05-05 07:24:47 2023-02-28 16:49:57 2022-11-07 16:36:02 2022-02-28 08:13:11 2021-03-08 17:17:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
revenue 84M 82M 283M 72M 71M 64M 289M 85M 68M 66M 619M 106M 993M 422M
costOfRevenue 49M 47M 176M 45M 47M 44M 185M 45M 47M 47M 252M 60M 216M 90M
grossProfit 36M 34M 107M 27M 25M 20M 104M 40M 21M 19M 367M 46M 777M 332M
grossProfitRatio 0.422 0.421 0.373 0.345 0.312 0.47 0.303 0.284 0.436
researchAndDevelopmentExpenses 14M 13M 49M 12M 13M 11M 41M 10M 10M 10M 29M 8M 24M 12M
generalAndAdministrativeExpenses 23M 26M 88M 21M 21M 21M 89M 17M 18M 22M 111M 26M 51M 15M
sellingAndMarketingExpenses 12M 12M 36M 9M 9M 9M 41M 10M 11M 10M 39M 10M 24M 15M
sellingGeneralAndAdministrativeExpenses 35M 39M 124M 30M 30M 30M 130M 28M 29M 32M 150M 36M 75M 30M
otherExpenses 2M 2M 8M 2M 2M 0 128M 2M 2M 2M 9M 2M 2M 0
operatingExpenses 51M 54M 181M 44M 43M 42M 300M 40M 40M 44M 188M 46M 101M 42M
costAndExpenses 99M 102M 357M 89M 90M 86M 485M 84M 88M 91M 440M 105M 317M 132M
interestIncome 8M 8M 31M 8M 8M 8M 22M 7M 5M 4M 6M 1M 1M 2M
interestExpense 28 000 17 000 170 000 14 000 0 0 488 000 54 000 206 000 -4M 1M 1M 0 0
depreciationAndAmortization 6M 6M 25M 6M 6M 7M 26M 6M 6M 2M 33M 2M 11M 3M
ebitda -77 001 -15M -49M -17M -13M -15M -147M 7M -13M -23M 218M 3M 687M 293M
ebitdaratio -0.001 -0.189 -0.238 -0.18 -0.235 0.078 -0.199 -0.345 0.024
operatingIncome -15M -20M -74M -17M -19M -22M -196M 214 000 -20M -25M 179M 562 000 676M 290M
operatingIncomeRatio -0.183 -0.241 -0.238 -0.266 -0.338 0.003 -0.292 -0.375 0.005
totalOtherIncomeExpensesNet 9M -2M 22M -1M 8M 8M 21M 7M 5M 4M 5M 1M 5M -3M
incomeBeforeTax -6M -22M -52M -19M -11M -14M -174M 7M -15M -21M 184M 2M 681M 287M
incomeBeforeTaxRatio -0.073 -0.263 -0.258 -0.158 -0.22 0.081 -0.217 -0.318 0.017
incomeTaxExpense 682 999 -2M -8M -4M -2M -327 000 1M 20M -3M -5M 42M 414 000 175M 73M
netIncome -7M -19M -43M -15M -9M -13M -168M -13M -11M -16M 143M 1M 507M 214M
netIncomeRatio -0.079 -0.232 -0.204 -0.123 -0.209 -0.155 -0.165 -0.24 0.013
eps -0.21 -0.61 -1.41 -0.48 -0.29 -0.45 -5.63 -0.44 -0.38 -0.54 4.76 0.045 17.13 9.44
epsdiluted -0.21 -0.61 -0.48 -0.29 -0.45 -0.44 -0.38 -0.54 0.044
weightedAverageShsOut 31M 31M 30M 30M 30M 30M 30M 30M 30M 30M 30M 30M 29M 23M
weightedAverageShsOutDil 31M 31M 30M 30M 30M 30M 30M 30M 30M 30M 31M 31M 31M 24M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-28 2023-02-28 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
netInterestIncome 31M 21M 5M 1M 2M
ebit -74M -174M 185M 676M 290M
nonOperatingIncomeExcludingInterest 0 -22M -7M 0 0
netIncomeFromContinuingOperations -44M -175M 142M 506M 214M
netIncomeFromDiscontinuedOperations 0 0 0 0 0
otherAdjustmentsToNetIncome 0 0 0 0 0
netIncomeDeductions 0 0 0 0 0
bottomLineNetIncome -43M -168M 143M 507M 214M
epsDiluted -1.41 -5.63 4.63 16.26 8.91

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-01 2024-11-08 2024-08-02 2024-05-03 2023-11-03 2023-08-04 2023-05-05 2022-11-07
acceptedDate 2025-11-07 07:14:18 2025-08-01 07:09:52 2025-02-28 07:15:43 2024-11-08 07:17:27 2024-08-02 07:38:25 2024-05-03 07:34:20 2024-02-28 17:03:25 2023-11-03 07:31:48 2023-08-04 07:14:47 2023-05-05 07:24:47 2023-02-28 16:49:57 2022-11-07 16:36:02 2022-02-28 08:13:11 2021-03-08 17:17:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
cashAndCashEquivalents 118M 88M 55M 58M 65M 55M 97M 84M 58M 66M 80M 169M 165M 87M
shortTermInvestments 258M 205M 203M 155M 247M 251M 327M 384M 400M 805M 447M 749M 286M 212M
cashAndShortTermInvestments 376M 293M 258M 213M 312M 306M 424M 468M 458M 871M 526M 918M 450M 299M
netReceivables 79M 85M 77M 57M 64M 59M 57M 55M 40M 44M 75M 104M 143M 204M
inventory 10M 9M 8M 9M 7M 7M 0 5M 6M 5M 4M 8M 12M 16M
otherCurrentAssets 43M 42M 0 48M 17M 21M 6M 33M 35M 33M 0 10M 0 0
totalCurrentAssets 507M 429M 354M 327M 399M 387M 508M 550M 528M 915M 628M 1 022M 612M 524M
propertyPlantEquipmentNet 112M 110M 106M 107M 103M 96M 96M 85M 88M 79M 81M 82M 62M 40M
goodwill 25M 22M 22M 22M 22M 22M 22M 142M 142M 143M 143M 120M 51M 0
intangibleAssets 135M 131M 135M 137M 139M 141M 143M 144M 146M 149M 151M 88M 36M 0
goodwillAndIntangibleAssets 160M 153M 157M 159M 161M 163M 165M 286M 288M 292M 294M 208M 87M 0
longTermInvestments 412M 484M 570M 602M 547M 561M 444M 399M 401M 380M 339M 358M 507M 133M
taxAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
otherNonCurrentAssets 23M 23M 33M 39M 23M 23M 23M 38M 49M -289M 44M -265M 11M 4M
totalNonCurrentAssets 707M 771M 866M 907M 833M 843M 727M 809M 826M 462M 758M 384M 667M 177M
otherAssets 0 0 0 0 0 0 0 0 0 0 0 0 0 0
totalAssets 1 215M 1 200M 1 220M 1 234M 1 232M 1 230M 1 235M 1 358M 1 355M 1 377M 1 386M 1 406M 1 279M 700M
accountPayables 18M 19M 18M 20M 20M 20M 15M 16M 21M 22M 23M 14M 20M 26M
shortTermDebt 2M 2M 412 000 412 000 3M 4M 1M 3M 5M 21M 21M 20M 21M 15M
taxPayables 0 0 0 0 0 0 0 0 0 0 0 426 000 787 000 53M
deferredRevenue 31M 30M 30M 27M 3M 3M 26M 21M 17M 14M 14M 28M 34M 27M
otherCurrentLiabilities 22M 21M 6M 27M 24M 50M 164 000 21M 23M 51M 5M 61M 11M -185 000
totalCurrentLiabilities 72M 71M 73M 74M 76M 76M 73M 61M 65M 108M 88M 124M 105M 130M
longTermDebt 6M 6M 2M 0 10M 2M 3M 3M 0 0 3M 0 0 0
deferredRevenueNonCurrent 0 0 0 0 8M 7M 0 -3M 0 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 7M 6M 6M 7M 13M 13M 8M 10M 10M 0 0 0 0 0
otherNonCurrentLiabilities 9M 5M 5M 18M 4M 5M 11M 25M 17M 26M 16M -42M 8M 391 000
totalNonCurrentLiabilities 21M 17M 18M 25M 28M 27M 29M 35M 26M 26M 28M 22M 8M 959 000
otherLiabilities 0 0 0 0 0 0 0 0 0 -26M 0 -22M 0 0
capitalLeaseObligations 5M 5M 6M 0 10M 7M 11M 10M 11M 0 15M 0 0 835 000
totalLiabilities 94M 88M 91M 99M 103M 103M 102M 97M 91M 108M 116M 124M 113M 131M
preferredStock 0 0 0 0 20M 20M 0 15M 13M 13M 0 0 0 0
commonStock 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000 3000
retainedEarnings 553M 560M 590M 596M 611M 620M 633M 761M 774M 786M 801M 825M 658M 151M
accumulatedOtherComprehensiveIncomeLoss 7M 6M -368 000 9M -877 000 -1M 1M -17M -21M -17M -21M -26M -759 000 438 000
othertotalStockholdersEquity 566M 551M 533M 522M 491M 499M 493M 487M 482M
totalStockholdersEquity 1 126M 1 117M 1 133M 1 138M 1 133M 1 130M 1 136M 1 259M 1 260M 1 269M 1 267M 1 281M 1 159M 569M
totalEquity 1 121M 1 112M 1 129M 1 135M 1 129M 1 127M 1 133M 1 262M 1 263M 1 273M 1 270M 1 281M 1 166M 569M
totalLiabilitiesAndStockholdersEquity 1 215M 1 200M 1 234M 1 232M 1 230M 1 358M 1 355M 1 377M 1 406M
minorityInterest -5M -5M -4M -4M -4M -3M -3M 3M 4M 4M 3M 0 7M 0
totalLiabilitiesAndTotalEquity 1 215M 1 200M 1 220M 1 234M 1 232M 1 230M 1 235M 1 358M 1 355M 1 377M 1 386M 1 406M 1 279M 700M
totalInvestments 670M 690M 773M 757M 793M 812M 771M 767M 788M 805M 786M 760M 793M 344M
totalDebt 8M 7M 8M 412 000 13M 13M 15M 3M 5M 21M 39M 20M 21M 16M
netDebt -110M -80M -47M -58M -52M -42M -82M -81M -54M -46M -41M -148M -144M -72M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-28 2023-02-28 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
accountsReceivables 69M 51M 53M 139M 184M
otherReceivables 8M 6M 22M 4M 20M
prepaids 10M 20M 22M 6M 4M
totalPayables 18M 15M 23M 21M 80M
otherPayables 0 0 0 787 000 53M
accruedExpenses 17M 27M 19M 18M 8M
capitalLeaseObligationsCurrent 1M 4M 6M 0 267 000
capitalLeaseObligationsNonCurrent 4M 7M 9M 0 568 000
treasuryStock 0 0 0 0 0
additionalPaidInCapital 543M 502M 487M 502M 418M
otherTotalStockholdersEquity 0 0 0 0 0

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q4 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3 2021 q4 2020 q4
date 2025-09-30 2025-06-30 2024-12-31 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30 2021-12-31 2020-12-31
symbol FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT FLGT
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-07 2025-08-01 2024-11-08 2024-08-02 2024-05-03 2023-11-03 2023-08-04 2023-05-05 2022-11-07
acceptedDate 2025-11-07 07:14:18 2025-08-01 07:09:52 2025-02-28 07:15:43 2024-11-08 07:17:27 2024-08-02 07:38:25 2024-05-03 07:34:20 2024-02-28 17:03:25 2023-11-03 07:31:48 2023-08-04 07:14:47 2023-05-05 07:24:47 2023-02-28 16:49:57 2022-11-07 16:36:02 2022-02-28 08:13:11 2021-03-08 17:17:13
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2022
period Q3 Q2 FY Q3 Q2 Q1 FY Q3 Q2 Q1 FY Q3 FY FY
netIncome -7M -19M -44M -15M -9M -13M -175M -13M -12M -16M 142M 1M 506M 214M
depreciationAndAmortization 6M 6M 25M 6M 6M 7M 26M 6M 6M 7M 33M 10M 11M 3M
deferredIncomeTax -701 000 24 000 -5M -2M -457 000 -557 000 8M 19M -3M -5M 831 000 3M -8M -1M
stockBasedCompensation 10M 10M 44M 11M 12M 12M 43M 11M 10M 10M 33M 9M 16M 8M
changeInWorkingCapital 2M -39M -7M -2M -3M 5M 3M -11M 9M -5M 2M -11M -3M -91M
accountsReceivables 5M -8M -16M -2M -3M 1M 2M -12M 10M 9M 69M 22M 42M -178M
inventory 0 0 0 0 0 0 0 0 0 0 0 0 0 0
accountsPayables -102 000 386 000 3M 2M 2M -245 000 -7M -3M -3M -2M -25M -22M -12M 23M
otherWorkingCapital -2M -31M 6M -3M -2M 4M 7M 3M 843 000 -7M -41M -12M -33M 64M
otherNonCashItems 495 000 11M 8M -12M 23M 22M 123M -2M -668 000 791 000 43M 9M 16M 8M
netCashProvidedByOperatingActivities 11M -30M 21M -16M 4M 7M 27M 10M 10M -8M 254M 21M 539M 141M
investmentsInPropertyPlantAndEquipment -6M -7M -40M -20M -13M -4M -22M -5M -12M -2M -19M -5M -24M -37M
acquisitionsNet 0 0 0 -275 000 17 000 258 000 -399 000 22 000 220 000 0 -183M 0 -62M -3M
purchasesOfInvestments -19M 0 -472M -115M -63M -196M -492M -93M -107M -144M -433M -12M -730M -324M
salesMaturitiesOfInvestments 40M 60M 454M 144M 83M 152M 553M 118M 117M 141M 373M 61M 270M 37M
otherInvestingActivites 4M 0 313 000 20M 258 000 25M 0 198 000 222 000
netCashUsedForInvestingActivites 19M 53M 9M 7M -47M 20M -1M -4M 44M
debtRepayment -88 000 -88 000 -136 000 -602 000 -900 000 -2M -16M -232 000 -238 000
commonStockIssued 0 0 0 0 0 0 3000 0 0
commonStockRepurchased -357 000 -3M -3M -431 000 -544 000 -225 000 -28M -2M -232 000 0 -76M -35M -4M -62 000
dividendsPaid 0 0 0 0 0 0 -229 000 0 0
otherFinancingActivites 0 0 0 -544 000 -2M -517 000 229 000 -869 000 -522 000
netCashUsedProvidedByFinancingActivities -445 000 -3M -567 000 -1M -3M -4M -16M -1M -35M
effectOfForexChangesOnCash 15 000 4000 -55 000 157 000 -9000 -69 000 -149 000 -116 000 -206 000 28 000 -453 000 387 000 34 000 20 000
netChangeInCash 30M 21M -42M -7M 10M -43M 18M 26M -8M -13M -85M 30M 77M 75M
cashAtEndOfPeriod 118M 88M 55M 58M 65M 55M 97M 84M 58M 66M 80M 169M 165M 87M
cashAtBeginningOfPeriod 88M 67M 97M 65M 55M 97M 80M 58M 66M 80M 165M 139M 87M 12M
operatingCashFlow 11M -30M 21M -16M 4M 7M 27M 10M 10M -8M 254M 21M 539M 141M
capitalExpenditure -6M -7M -40M -20M -13M -4M -22M -5M -12M -2M -19M -5M -24M -37M
freeCashFlow 5M -37M -19M -35M -9M 3M 5M 5M -2M -10M 235M 15M 515M 104M
link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link
filingDate 2025-02-28 2024-02-28 2023-02-28 2022-02-28 2021-03-08
fiscalYear 2024 2023 2022 2021 2020
otherInvestingActivities 313 000 775 000 412 000 31 000 8000
netCashProvidedByInvestingActivities -58M 39M -261M -547M -326M
netDebtIssuance -2M -20M -1M -11 000 15M
longTermNetDebtIssuance -544 000 -730 000 -700 000 -7000 0
shortTermNetDebtIssuance -1M -19M -367 000 -4000 15M
netStockIssuance -3M -28M -76M 85M 246M
netCommonStockIssuance -3M -28M -76M 85M 246M
commonStockIssuance 0 0 0 89M 246M
netPreferredStockIssuance 0 0 0 0 0
netDividendsPaid 0 0 0 0 0
commonDividendsPaid 0 0 0 0 0
preferredDividendsPaid 0 0 0 0 0
otherFinancingActivities 51 000 3000 31 000 96 000 104 000
netCashProvidedByFinancingActivities -5M -48M -77M 85M 261M
incomeTaxesPaid 28M 3M 56M 237M 21M
interestPaid 512 000 960 000 0 0 0

Earning call transcript

2025 q3
2025-11-07 ET (fiscal 2025 q3)
2025 q2
2025-08-01 ET (fiscal 2025 q2)
2025 q1
2025-05-02 ET (fiscal 2025 q1)
2024 q4
2025-02-28 ET (fiscal 2024 q4)
2024 q3
2024-11-11 ET (fiscal 2024 q3)
2024 q2
2024-08-02 ET (fiscal 2024 q2)
2024 q1
2024-05-03 ET (fiscal 2024 q1)
2023 q4
2024-02-28 ET (fiscal 2023 q4)
2023 q3
2023-11-03 ET (fiscal 2023 q3)
2023 q2
2023-08-04 ET (fiscal 2023 q2)
2023 q1
2023-05-05 ET (fiscal 2023 q1)
2022 q4
2023-02-28 ET (fiscal 2022 q4)
2022 q3
2022-11-07 ET (fiscal 2022 q3)
2022 q2
2022-08-04 ET (fiscal 2022 q2)
2022 q1
2022-05-03 ET (fiscal 2022 q1)

Press-releases

Show financial reports only

2026-05-21 21:03 ET
Fulgent Announces Rapid Oral Full Abstract Publication for FID-007 Within the Head and Neck Cancer Track Session at the ASCO 2026 Annual Meeting
2026-05-04 ET
Foundation Medicine to Launch FoundationOne®PGx, a Pharmacogenetic Offering, Through Expanded Partnership with Fulgent Genetics
2026-05-01 ET
Fulgent Reports First Quarter 2026 Financial Results
2026-04-22 ET
Fulgent Selected to Present Rapid Oral Abstract Within the Head and Neck Cancer Track Session at the 2026 ASCO Annual Meeting
2026-04-16 ET
Fulgent to Announce First Quarter 2026 Financial Results on Friday, May 1, 2026
2026-03-17 ET
Fulgent Genetics Completes Acquisition of Bako Diagnostics and StrataDx
2026-03-13 ET
Fulgent Genetics, Inc. Investigated by the Portnoy Law Firm
2026-03-12 ET
Lowey Dannenberg, P.C. is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) for Potential Violations of the Federal Securities Laws and Encourages Investors to Contact the Firm
2026-03-02 ET
Fulgent Genetics, Inc. Shareholders Are Encouraged to Reach Out to Johnson Fistel for More Information About Potentially Recovering Their Losses
2026-02-27 ET
Fulgent Reports Fourth Quarter and Full Year 2025 Financial Results
2026-02-12 12:30 ET
Fulgent to Announce Fourth Quarter and Full Year 2025 Financial Results on Friday, February 27, 2026
2025-12-22 ET
Fulgent Genetics Agrees to Acquire Bako Diagnostics and StrataDx
2025-11-07 12:05 ET
Fulgent Reports Third Quarter 2025 Financial Results
2025-11-07 ET
Fulgent to Participate in Upcoming Conferences
2025-10-20 ET
Fulgent Shares Preliminary Data from Poster Presentation at ESMO 2025 Conference
2025-10-16 ET
Fulgent to Announce Third Quarter 2025 Financial Results on Friday, November 7, 2025
2025-08-01 ET
Fulgent Reports Second Quarter 2025 Financial Results
2025-07-17 ET
Fulgent Genetics Receives EU CE Mark for FulgentExome & FulgentPLM
2025-07-10 ET
Fulgent to Announce Second Quarter 2025 Financial Results on Friday, August 1, 2025
2025-05-02 ET
Fulgent Reports First Quarter 2025 Financial Results
2025-04-10 ET
Fulgent to Announce First Quarter 2025 Financial Results on Friday, May 2, 2025
2025-02-28 ET
Fulgent Reports Fourth Quarter and Full Year 2024 Financial Results
2025-02-06 ET
Fulgent to Announce Fourth Quarter and Full Year 2024 Financial Results on Friday, February 28, 2025
2025-02-04 ET
Foundation Medicine to Launch Hereditary Germline Tests, FoundationOne®Germline and FoundationOne®Germline More, in the United States Through a Partnership with Fulgent Genetics
2024-11-08 ET
Fulgent Reports Third Quarter 2024 Financial Results
2024-11-05 13:00 ET
Fulgent to Participate in Upcoming Conferences
2024-10-31 12:00 ET
Fulgent Genetics Awarded Contract by the U.S. Department of Veterans Affairs to Provide Hereditary Cancer, Pharmacogenetic and Other Genetic Testing to Veterans¹
2024-10-17 20:05 ET
Fulgent to Announce Third Quarter 2024 Financial Results on Friday, November 8, 2024
2024-08-02 11:00 ET
Fulgent Reports Second Quarter 2024 Financial Results 
2024-07-11 20:05 ET
Fulgent to Announce Second Quarter 2024 Financial Results on Friday, August 2, 2024
2024-06-03 12:00 ET
Fulgent Data at ASCO 2024 Highlights Antitumor Activity from Lead Therapeutic Oncology Candidate, FID-007, in Head and Neck Cancer
2024-05-24 12:00 ET
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2024 Annual Meeting
2024-05-14 20:05 ET
Moffitt Cancer Center and Fulgent Pharma Join Forces to Revolutionize Cancer Therapeutics
2024-05-03 11:00 ET
Fulgent Reports First Quarter 2024 Financial Results
2024-04-11 20:05 ET
Fulgent Genetics to Announce First Quarter 2024 Financial Results on Friday, May 3, 2024
2024-02-28 12:00 ET
Fulgent Reports Fourth Quarter and Full Year 2023 Financial Results
2024-02-13 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2023 Financial Results on Wednesday, February 28, 2024
2024-02-09 13:31 ET
Cord Blood Registry® (CBR®) by CooperSurgical® and Fulgent Genetics Launch Innovative Genetic Testing
2023-11-14 21:30 ET
Fulgent to Participate in the Piper Sandler 35th Annual Healthcare Conference
2023-11-03 20:05 ET
Fulgent Shares Data from Two Poster Presentations at SITC 2023 Annual Meeting
2023-11-03 11:00 ET
Fulgent Reports Third Quarter 2023 Financial Results
2023-10-25 12:00 ET
Fulgent Announces Two Poster Presentations at SITC 2023 Annual Meeting
2023-10-17 12:00 ET
Fulgent Genetics to Announce Third Quarter 2023 Financial Results on Friday November 3, 2023
2023-08-04 11:00 ET
Fulgent Reports Second Quarter 2023 Financial Results
2023-07-18 12:00 ET
Fulgent Genetics to Announce Second Quarter 2023 Financial Results on Friday, August 4, 2023
2023-06-05 12:30 ET
Fulgent Data at ASCO 2023 Highlights Progress for Its Lead Therapeutic Oncology Candidate, FID-007, in Various Cancers
2023-05-18 20:05 ET
Fulgent Announces Upcoming Presentation of Clinical Data for Its Lead Therapeutic Oncology Candidate, FID-007, at ASCO 2023 Annual Meeting
2023-05-05 11:00 ET
Fulgent Reports First Quarter 2023 Financial Results
2023-04-20 20:05 ET
Fulgent Genetics to Announce First Quarter 2023 Financial Results on Friday May 5, 2023
2023-04-11 12:00 ET
Mission Bio Partners with Fulgent Genetics to Broaden Accessibility of Single-Cell Multi-Omics for Drug Development and Clinical Research
2023-02-28 21:05 ET
Fulgent Reports Fourth Quarter and Full Year 2022 Financial Results
2023-02-28 21:03 ET
Fulgent Genetics Launches New Beacon787 Expanded Carrier Screening Panel
2023-02-23 21:05 ET
Fulgent to Participate in the Raymond James & Associates’ 44th Annual Institutional Investors Conference
2023-02-14 21:05 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2022 Financial Results on Tuesday, February 28, 2023
2023-01-03 21:05 ET
Fulgent Expands Board of Directors with Addition of Reggie Groves
2022-12-27 14:30 ET
Barrack, Rodos & Bacine (BR&B) Is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) For Potential Investor Claims
2022-12-27 ET
Barrack, Rodos & Bacine (BR&B) Is Investigating Fulgent Genetics Inc. (NASDAQ: FLGT) For Potential Investor Claims
2022-11-17 21:05 ET
Fulgent Genetics to Participate in Piper Sandler’s 34th Annual Healthcare Conference
2022-11-07 21:06 ET
Fulgent Genetics Acquires Fulgent Pharma, Creating a New Paradigm in Precision Medicine for The Company
2022-11-07 21:05 ET
Fulgent Genetics Reports Third Quarter 2022 Financial Results
2022-10-25 20:03 ET
Fulgent Genetics to Participate in Credit Suisse’s 31st Annual Healthcare Conference
2022-10-20 20:03 ET
Fulgent Genetics to Announce Third Quarter 2022 Financial Results on Monday November 7, 2022
2022-09-23 13:51 ET
INVESTOR ALERT: Edelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Fulgent Genetics, Inc. (NASDAQ: FLGT) Shareholders
2022-09-23 ET
INVESTOR ALERT: Edelson Lechtzin LLP is Investigating Securities Fraud Claims on Behalf of Fulgent Genetics, Inc. (NASDAQ: FLGT) Shareholders
2022-08-04 20:05 ET
Fulgent Genetics Reports Second Quarter 2022 Financial Results
2022-08-04 12:00 ET
Fulgent Genetics Welcomes Dr. Michael Nohaile and Dr. Leonard Post to Board of Directors
2022-08-04 12:00 ET
Fulgent Genetics Announces Launch of PCR Based Test to Detect Monkeypox
2022-07-19 12:00 ET
Fulgent Genetics to Announce Second Quarter 2022 Financial Results on Thursday, August 4, 2022
2022-07-05 12:00 ET
The American Medical Association Approves a New Category I CPT® Code for the HelioLiver™ Test
2022-05-03 20:05 ET
Fulgent Genetics Announces Promotions and Leadership Updates
2022-05-03 20:05 ET
Fulgent Genetics Reports First Quarter 2022 Financial Results
2022-05-03 12:00 ET
Fulgent Genetics Announces Opening of New State-of-the-Art Oncology Laboratory in El Monte, California
2022-04-27 16:05 ET
AVISTA CAPITAL PARTNERS COMPLETES SALE OF INFORM DIAGNOSTICS TO FULGENT GENETICS, INC.
2022-04-18 20:05 ET
Fulgent Genetics Agrees to Acquire Inform Diagnostics and Provides Preliminary First Quarter Revenue Results
2022-04-18 20:03 ET
Fulgent Genetics to Announce First Quarter 2022 Financial Results on Tuesday, May 3, 2022
2022-03-08 13:00 ET
Representatives of Fulgent Genetics to Participate in Oppenheimer’s 32nd Annual Healthcare Conference
2022-03-08 13:00 ET
Fulgent Genetics Announces $250 Million Share Repurchase Program
2022-03-08 ET
Fulgent Genetics Announces $250 Million Share Repurchase Program
2022-03-07 13:00 ET
Helio Health Announces Publication of ENCORE Data in Hepatology Communications, Demonstrating Superior Performance of HelioLiver for Early Detection of Liver Cancer
2022-02-24 14:00 ET
EPIC SCIENCES AND FULGENT GENETICS COLLABORATE TO DELIVER DefineMBC™ RESULTS FOR METASTATIC BREAST CANCER PATIENTS
2022-02-23 21:05 ET
Fulgent Genetics Announces Strategic Investment in Spatial Genomics
2022-02-23 21:05 ET
Fulgent Genetics Reports Fourth Quarter and Full Year 2021 Financial Results
2022-02-14 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2021 Financial Results on Wednesday February 23, 2022
2021-12-06 13:00 ET
HelioLiver™, an Innovative Liquid Biopsy Test for the Early Detection of Liver Cancer, is Now Commercially Available
2021-12-01 21:40 ET
Fulgent Genetics Confirms Ability to Detect Omicron Variant with RT-PCR Tests for COVID-19
2021-11-09 21:05 ET
Fulgent Genetics Reports Third Quarter Financial Results
2021-11-09 13:00 ET
Representatives of Fulgent Genetics to Participate in Upcoming Virtual Conferences
2021-11-08 13:00 ET
Helio Health and Fulgent Genetics Announce Late-Breaking Positive Performance Data of HelioLiver™ for Early Liver Cancer Detection
2021-11-01 20:05 ET
Helio Health and Fulgent Genetics to Present New Data on HelioLiver in Late-Breaking Presentation at The Liver Meeting® 2021
2021-10-27 12:00 ET
Fulgent Genetics Launches At-Home Neutralizing Antibody Test for COVID-19
2021-10-25 12:00 ET
Fulgent Genetics to Announce Third Quarter 2021 Financial Results on Tuesday November 9, 2021
2021-09-23 20:05 ET
Fulgent Genetics to Partner with Houston Health Department and Houston-Area Public Schools on Back-to-School COVID-19 Testing Program
2021-08-09 20:05 ET
Fulgent Genetics Reports Second Quarter Financial Results
2021-08-09 20:02 ET
Fulgent Genetics Announces Acquisition of CSI Laboratories
2021-08-09 20:02 ET
Fulgent Genetics and Helio Health Announce Strategic Partnership to Commercialize Early Cancer Detection Tests
2021-07-26 12:00 ET
CORRECTING and REPLACING Fulgent Genetics to Announce Second Quarter 2021 Financial Results on Monday, August 9, 2021
2021-05-10 12:00 ET
Fulgent Genetics Announces Incremental Strategic Investment in Chinese Joint Venture, FF Gene Biotech
2021-05-06 20:05 ET
Fulgent Genetics Reports Record First Quarter Financial Results
2021-05-06 12:00 ET
Fulgent Genetics Welcomes Dr. Lawrence Weiss as Chief Medical Officer
2021-04-16 12:00 ET
Fulgent Genetics to Announce First Quarter 2021 Financial Results on Thursday May 6, 2021
2021-03-15 20:05 ET
Fulgent Genetics Awarded Contract from CDC to Study Variants of COVID-19 Virus
2021-03-05 13:00 ET
Fulgent Genetics to Participate in the Oppenheimer 31st Annual Healthcare Conference
2021-03-04 21:05 ET
Fulgent Genetics Reports Record Fourth Quarter and Full Year 2020 Financial Results
2021-02-18 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2020 Financial Results on Thursday March 4, 2021
2021-02-16 15:00 ET
BioIQ Partners with Fulgent Genetics to Bring COVID-19 Variant Detection to COVID-19 Testing Programs
2021-01-06 13:00 ET
Fulgent Genetics to Participate in the H.C. Wainwright BIOCONNECT 2021 Conference
2020-12-29 13:00 ET
Fulgent Genetics Extends Partnership with New York City Test and Trace for COVID-19 Testing, Awarded Contract for 2021 School Year
2020-12-17 21:02 ET
PRA Health Sciences collaborates with PWNHealth and Fulgent Genetics to provide at-home COVID-19 test capabilities
2020-11-24 13:00 ET
Fulgent Genetics to Participate in the Piper Sandler 32nd Annual Healthcare Conference
2020-11-23 13:00 ET
Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million
2020-11-23 ET
Fulgent Genetics Announces Increase to Full Year 2020 Guidance to $300 million
2020-11-18 13:30 ET
LANES, Fulgent Genetics and LA County Department of Health Services Collaborate to Fast-Track COVID-19 Test Results to Local Healthcare Providers
2020-11-10 21:05 ET
Fulgent Genetics to Participate in the Credit Suisse 29th Annual Virtual Healthcare Conference
2020-11-09 21:05 ET
Fulgent Genetics Reports Record Third Quarter 2020 Financial Results and Raises Full Year 2020 Revenue Guidance by $100 Million
2020-10-26 12:00 ET
Fulgent Genetics to Announce Third Quarter 2020 Financial Results on Monday November 9, 2020
2020-09-30 12:00 ET
Fulgent Genetics Announces Partnership with Ohio Department of Rehabilitation and Correction for COVID-19 Testing
2020-09-21 22:41 ET
Fulgent Genetics Set to Join S&P SmallCap 600
2020-09-15 12:00 ET
Fulgent Genetics to Provide COVID-19 Testing Solutions for the State of Utah
2020-09-09 12:00 ET
Fulgent Genetics, Miami-Dade County Partner on COVID-19 testing
2020-09-04 12:00 ET
Fulgent Genetics to Participate in the H.C. Wainwright 22nd Annual Global Investment Conference
2020-09-03 10:00 ET
Fulgent Genetics Adds Influenza A and Influenza B to all COVID-19 Tests
2020-09-02 20:05 ET
Fulgent Genetics, New York City Health and Hospitals Partner on Large-Scale Back-to-School COVID-19 Testing
2020-08-17 11:00 ET
Fulgent Genetics Announces Expansion into Houston, TX
2020-08-04 20:05 ET
Fulgent Genetics Reports Record Second Quarter 2020 Financial Results
2020-07-14 12:00 ET
Fulgent Genetics to Announce Second Quarter 2020 Financial Results on Tuesday August 4, 2020
2020-06-16 20:05 ET
Fulgent Genetics Announces FDA Authorization and Launch of At-Home Testing Service for COVID-19 
2020-05-18 10:00 ET
Fulgent Genetics Receives Emergency Use Authorization from the FDA for its RT-PCR Test for Detection of SARS-CoV-2, the Virus that Causes COVID-19
2020-05-04 20:05 ET
Fulgent Genetics Reports First Quarter 2020 Financial Results
2020-04-09 12:01 ET
Fulgent Genetics to Announce First Quarter 2020 Financial Results on Monday May 4, 2020
2020-04-09 12:00 ET
Fulgent Genetics Provides Update on Testing for COVID-19
2020-03-17 12:00 ET
Fulgent Genetics Announces Launch of Next Generation Sequencing (NGS) Test to Detect Coronavirus Disease (COVID-19)
2020-03-10 20:05 ET
Fulgent Genetics Reports Fourth Quarter and Full Year 2019 Financial Results
2020-03-10 12:00 ET
Fulgent Genetics Announces Promotion of Brandon Perthuis to Chief Commercial Officer
2020-02-20 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2019 Financial Results on Tuesday March 10, 2020
2019-11-25 13:00 ET
Representatives of Fulgent Genetics to Participate in the Piper Jaffray 31st Annual Healthcare Conference
2019-11-14 04:15 ET
Fulgent Genetics Announces Pricing of Public Offering of Common Stock
2019-11-13 21:01 ET
Fulgent Genetics Announces Proposed Public Offering of Common Stock
2019-11-04 21:05 ET
Fulgent Genetics Reports Third Quarter 2019 Financial Results
2019-10-15 12:00 ET
Fulgent Genetics to Announce Third Quarter 2019 Financial Results on Monday November 4, 2019
2019-09-16 12:00 ET
Fulgent Genetics Launches Picture Genetics, a Consumer-Initiated Genetic Testing Offering
2019-04-18 12:00 ET
Fulgent Genetics to Announce First Quarter 2019 Financial Results on Tuesday May 7, 2019
2019-02-28 21:05 ET
Fulgent Genetics Reports Fourth Quarter and Full Year 2018 Financial Results
2019-02-20 13:00 ET
Fulgent Genetics to Announce Fourth Quarter and Full Year 2018 Financial Results on Thursday February 28, 2019

SEC forms

Show financial reports only

SEC form 10
2026-02-27 07:15 ET
Fulgent Genetics published news for 2025 q4
SEC form 8
2026-02-27 07:04 ET
Fulgent Genetics published news for 2025 q4
SEC form 8
2026-02-27 07:04 ET
Fulgent Genetics published news for 2025 q4
SEC form 8
2026-02-27 07:04 ET
Fulgent Genetics published news for 2025 q4
SEC form 8
2025-12-22 21:11 ET
Fulgent Genetics published news for 2025 q3
SEC form 8
2025-12-22 21:11 ET
Fulgent Genetics published news for 2025 q3
SEC form 8
2025-12-22 21:11 ET
Fulgent Genetics published news for 2025 q3
SEC form 8
2025-12-22 21:11 ET
Fulgent Genetics published news for 2025 q3
SEC form 10
2025-11-07 07:14 ET
Fulgent Genetics published news for 2025 q3
SEC form 8
2025-11-07 07:10 ET
Fulgent Genetics published news for 2025 q3
SEC form 8
2025-11-07 07:10 ET
Fulgent Genetics reported for 2025 q3
SEC form 8
2025-11-07 07:10 ET
Fulgent Genetics published news for 2025 q3
SEC form 8
2025-10-20 10:04 ET
Fulgent Genetics published news for 2025 q3
SEC form 8
2025-10-20 10:04 ET
Fulgent Genetics published news for 2025 q3
SEC form 10
2025-08-01 07:09 ET
Fulgent Genetics reported for 2025 q2
SEC form 8
2025-08-01 07:05 ET
Fulgent Genetics published news for 2025 q2
SEC form 8
2025-08-01 07:05 ET
Fulgent Genetics published news for 2025 q2
SEC form 8
2025-08-01 07:05 ET
Fulgent Genetics published news for 2025 q2
SEC form 10
2025-05-02 11:14 ET
Fulgent Genetics published news for 2025 q1
SEC form 8
2025-05-02 11:10 ET
Fulgent Genetics published news for 2025 q1
SEC form 8
2025-05-02 11:10 ET
Fulgent Genetics reported for 2025 q1
SEC form 8
2025-05-02 11:10 ET
Fulgent Genetics published news for 2025 q1
SEC form 10
2025-05-02 00:00 ET
Fulgent Genetics published news for 2025 q1
SEC form 10
2025-02-28 07:15 ET
Fulgent Genetics reported for 2024 q4
SEC form 8
2025-02-28 07:10 ET
Fulgent Genetics published news for 2024 q4
SEC form 8
2025-02-28 07:10 ET
Fulgent Genetics published news for 2024 q4
SEC form 8
2025-02-28 07:10 ET
Fulgent Genetics published news for 2024 q4
SEC form 10
2025-02-28 00:00 ET
Fulgent Genetics published news for 2024 q4
SEC form 10
2024-11-08 07:17 ET
Fulgent Genetics reported for 2024 q3
SEC form 8
2024-11-08 07:10 ET
Fulgent Genetics published news for 2024 q3
SEC form 8
2024-11-08 07:10 ET
Fulgent Genetics published news for 2024 q3
SEC form 8
2024-11-08 07:10 ET
Fulgent Genetics published news for 2024 q3
SEC form 10
2024-08-02 07:38 ET
Fulgent Genetics published news for 2024 q2
SEC form 8
2024-08-02 07:09 ET
Fulgent Genetics published news for 2024 q2
SEC form 8
2024-08-02 07:09 ET
Fulgent Genetics reported for 2024 q2
SEC form 8
2024-08-02 07:09 ET
Fulgent Genetics published news for 2024 q2
SEC form 10
2024-08-02 00:00 ET
Fulgent Genetics published news for 2024 q2
SEC form 10
2024-05-03 07:34 ET
Fulgent Genetics published news for 2024 q1
SEC form 8
2024-05-03 07:05 ET
Fulgent Genetics published news for 2024 q1
SEC form 8
2024-05-03 07:05 ET
Fulgent Genetics reported for 2024 q1
SEC form 8
2024-05-03 07:05 ET
Fulgent Genetics published news for 2024 q1
SEC form 10
2024-05-03 00:00 ET
Fulgent Genetics published news for 2024 q1
SEC form 10
2024-02-28 17:03 ET
Fulgent Genetics published news for 2023 q4
SEC form 8
2024-02-28 07:08 ET
Fulgent Genetics published news for 2023 q4
SEC form 8
2024-02-28 07:08 ET
Fulgent Genetics reported for 2023 q4
SEC form 8
2024-02-28 07:08 ET
Fulgent Genetics published news for 2023 q4
SEC form 10
2024-02-28 00:00 ET
Fulgent Genetics published news for 2023 q4
SEC form 10
2023-11-03 07:31 ET
Fulgent Genetics published news for 2023 q3
SEC form 8
2023-11-03 07:09 ET
Fulgent Genetics reported for 2023 q3
SEC form 10
2023-11-03 00:00 ET
Fulgent Genetics published news for 2023 q3
SEC form 10
2023-08-04 07:14 ET
Fulgent Genetics reported for 2023 q2
SEC form 6
2023-08-04 07:07 ET
Fulgent Genetics published news for 2023 q2
SEC form 10
2023-08-04 00:00 ET
Fulgent Genetics published news for 2023 q2
SEC form 8
2023-08-04 00:00 ET
Fulgent Genetics published news for 2023 q2
SEC form 10
2023-05-05 00:00 ET
Fulgent Genetics published news for 2023 q1
SEC form 8
2023-05-05 00:00 ET
Fulgent Genetics published news for 2023 q1
SEC form 10
2023-02-28 16:49 ET
Fulgent Genetics reported for 2022 q4
SEC form 6
2023-02-28 16:24 ET
Fulgent Genetics published news for 2022 q4
SEC form 10
2023-02-28 00:00 ET
Fulgent Genetics reported for 2022 q4
SEC form 8
2023-02-28 00:00 ET
Fulgent Genetics reported for 2022 q4
SEC form 6
2023-01-12 16:10 ET
Fulgent Genetics published news for 2022 q4
SEC form 6
2023-01-04 16:34 ET
Fulgent Genetics published news for 2022 q4
SEC form 6
2023-01-03 16:11 ET
Fulgent Genetics published news for 2022 q4
SEC form 6
2022-11-23 16:09 ET
Fulgent Genetics published news for 2022 q3
SEC form 10
2022-11-07 16:36 ET
Fulgent Genetics reported for 2022 q3
SEC form 6
2022-11-07 16:11 ET
Fulgent Genetics published news for 2022 q3
SEC form 10
2022-11-07 00:00 ET
Fulgent Genetics reported for 2022 q3
SEC form 8
2022-11-07 00:00 ET
Fulgent Genetics reported for 2022 q3
SEC form 6
2022-11-04 16:05 ET
Fulgent Genetics published news for 2022 q3
SEC form 6
2022-09-29 16:15 ET
Fulgent Genetics published news for 2022 q2
SEC form 6
2022-08-10 18:06 ET
Fulgent Genetics published news for 2022 q2
SEC form 10
2022-08-04 17:03 ET
Fulgent Genetics reported for 2022 q2
SEC form 6
2022-08-04 16:39 ET
Fulgent Genetics published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Fulgent Genetics reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Fulgent Genetics reported for 2022 q2
SEC form 6
2022-08-03 17:34 ET
Fulgent Genetics published news for 2022 q2
SEC form 6
2022-06-30 16:07 ET
Fulgent Genetics published news for 2022 q1
SEC form 6
2022-05-19 16:19 ET
Fulgent Genetics published news for 2022 q1
SEC form 10
2022-05-05 16:51 ET
Fulgent Genetics reported for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Fulgent Genetics reported for 2022 q1
SEC form 6
2022-05-03 16:10 ET
Fulgent Genetics published news for 2022 q1
SEC form 8
2022-05-03 00:00 ET
Fulgent Genetics reported for 2022 q1
SEC form 6
2022-04-26 16:43 ET
Fulgent Genetics published news for 2022 q1
SEC form 6
2022-04-18 16:13 ET
Fulgent Genetics published news for 2022 q1
SEC form 6
2022-03-29 16:33 ET
Fulgent Genetics published news for 2021 q4
SEC form 6
2022-03-29 16:23 ET
Fulgent Genetics published news for 2021 q4
SEC form 10
2022-02-28 08:13 ET
Fulgent Genetics published news for 2021 q4
SEC form 10
2022-02-28 00:00 ET
Fulgent Genetics published news for 2021 q4
SEC form 6
2022-02-23 16:10 ET
Fulgent Genetics published news for 2021 q4
SEC form 8
2022-02-23 00:00 ET
Fulgent Genetics published news for 2021 q4
SEC form 10
2021-11-09 17:13 ET
Fulgent Genetics published news for 2021 q3
SEC form 6
2021-11-09 16:11 ET
Fulgent Genetics published news for 2021 q3
SEC form 10
2021-11-09 00:00 ET
Fulgent Genetics published news for 2021 q3
SEC form 8
2021-11-09 00:00 ET
Fulgent Genetics published news for 2021 q3
SEC form 10
2021-08-10 00:00 ET
Fulgent Genetics published news for 2021 q2
SEC form 10
2021-08-09 21:32 ET
Fulgent Genetics published news for 2021 q2
SEC form 6
2021-08-09 16:25 ET
Fulgent Genetics published news for 2021 q2
SEC form 6
2021-05-20 17:12 ET
Fulgent Genetics published news for 2021 q1
SEC form 10
2021-05-07 16:07 ET
Fulgent Genetics published news for 2021 q1
SEC form 10
2021-05-07 00:00 ET
Fulgent Genetics published news for 2021 q1
SEC form 6
2021-05-06 16:20 ET
Fulgent Genetics published news for 2021 q1
SEC form 6
2021-04-01 16:16 ET
Fulgent Genetics published news for 2021 q1
SEC form 10
2021-03-08 17:17 ET
Fulgent Genetics published news for 2020 q4
SEC form 6
2021-03-04 16:07 ET
Fulgent Genetics published news for 2020 q4
SEC form 6
2021-02-05 16:40 ET
Fulgent Genetics published news for 2020 q4
SEC form 6
2020-12-22 17:08 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-11-23 08:12 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-11-20 17:03 ET
Fulgent Genetics published news for 2020 q3
SEC form 10
2020-11-09 16:24 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-11-09 16:11 ET
Fulgent Genetics published news for 2020 q3
SEC form 6
2020-10-21 16:17 ET
Fulgent Genetics published news for 2020 q3